Vertex Pharmaceuticals VRTX announced that the FDA has accepted its biologics license application (BLA) seeking approval for its investigational candidate, povetacicept, for treating adults with ...

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free ...

If you are wondering whether Vertex Pharmaceuticals at around US$438 per share is priced attractively or already reflects its ...

Should you take advantage of recent losses to buy Vertex on the dip before the new year? Or is the recent clinical trial news a warning for investors? Let's find out. First, let's consider the Vertex ...

It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 0.2% in that time frame, underperforming the S&P 500. Will the recent positive trend ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the loss ...

Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook ...

The Vertex Companies Inc. (VERTEX) is pleased to announce the acquisition of Lockwood, Kessler & Bartlett, Inc. (LKB), a premier engineering design and construction administration firm headquartered ...

A Decade After Pioneering Nation-State-Grade CTI for the Private Sector, Vertex Releases Anniversary Podcast Series Exploring the Past and Future of Intelligence-Driven Security Since its founding in ...